Gastroparesis Consortium Continuation and New Type 2 Diabetes Mellitus Studiies

描述（由申请人提供）：维克森林大学的这一提议是继续作为胃分离临床研究联盟（GpCRC）的临床中心，并继续对我们迄今为止招募到登记研究的105例患者进行出色的随访和保留。此外，我们将继续入组登记研究并完成三项治疗试验（NORIG、GLUMIT-DG、APRON）。我们还将利用联盟和登记处的资源，继续调查胃轻瘫的病因学、流行病学、发病率和死亡率。我中心将支持Farrugia博士在明尼苏达州罗切斯特的马约诊所进行的胃轻瘫病理基础研究，以确定参与胃轻瘫发病机制的分子因素，因为我们制定了胃刺激剂治疗计划。自2006年以来，由NIDDK赞助的GpCRC的目标是关注胃轻瘫的病因、治疗策略和临床过程，我们将继续支持联盟和数据协调中心（DCC）设计和执行方案，及时向DCC提供数据，制定出版优先级，并创建摘要和手稿以供出版。我们的网站将继续充分参与所有协调员和指导委员会的活动。我们还将继续与NIDDK生物样品、遗传和数据库进行有效合作。2型糖尿病（T2 DM）患者会出现胃轻瘫和相关症状。我们的网站具体的建议是调查胃动力和神经内分泌异常的2型糖尿病患者。我们假设这些神经内分泌缺陷影响：a）胃的肌电和收缩特性，以及B）随时间以不同方式释放控制胰岛素分泌以及饥饿和饱腹感的肠道激素（GLP-1、GIP、胃饥饿素、VIP和NPY）。我们建议调查从糖尿病前期到晚期2型糖尿病（诊断后>10年）的个体对混合餐的胃神经肌肉和内分泌反应。

DESCRIPTION (provided by applicant): This proposal from Wake Forest University is to continue as a Clinical Center in the Gastoparesis Clinical Research Consortium (GpCRC) and to continue our excellent follow up and retention of the 105 patients we have thus far recruited to the Registry. In addition, we will continue enrollment into the Registry and complete three treatment trials (NORIG, GLUMIT-DG, APRON). We will also utilize the resources of the Consortium and the Registry to continue to investigate the etiology, epidemiology, and morbidity and mortality associated with gastroparesis. Our center will support the Pathological Basis of Gastroparesis Study conducted by Dr. Farrugia at the Mayo Clinic in Rochester, MN for identification of the molecular factors involved in pathogenesis of gastroparesis as we institute a program of gastric stimulator therapy. The goal of the GpCRC sponsored by the NIDDK since 2006 is to focus on the etiology, treatment strategies, and clinical course of gastroparesis and we will continue to support the Consortium and Data Coordinating Center (DCC) in designing and carrying out the protocols, providing data in a timely manner to the DCC, developing publication priorities, and creating abstracts and manuscripts for publication. Our site will continue to participate fully in all Coordinator and Steering Committee activities. We will also continue to work efficiently with the NIDDK Biosample, Genetic and Data Repositories. Patients with Type 2 diabetes mellitus (T2DM) develop gastroparesis and associated symptoms. Our site specific proposal is to investigate gastric motility and neuro-endocrinological abnormalities in patients with Type 2 diabetes. We hypothesize that these neuro-endocrine defects affect; a) myoelectrical and contractile properties of the stomach and, b) the release of gut hormones which control insulin secretions and hunger and satiety (GLP-1, GIP, ghrelin, VIP and NPY) in a differential manner over time. We propose to investigate the gastric neuromuscular and the endocrinologic reponses to a mixed meal in individuals ranging from pre-diabetes to late Type 2 diabetes (>10 years since diagnosis).